sb-435495 and darapladib

sb-435495 has been researched along with darapladib* in 1 studies

Other Studies

1 other study(ies) available for sb-435495 and darapladib

Article	Year
The identification of clinical candidate SB-480848: a potent inhibitor of lipoprotein-associated phospholipase A2. Bioorganic & medicinal chemistry letters, 2003, Mar-24, Volume: 13, Issue:6 Modification of the pyrimidone 5-substituent in clinical candidate SB-435495 has given a series of inhibitors of recombinant lipoprotein-associated phospholipase A(2) with sub-nanomolar potency. Cyclopentyl fused derivative 21, SB-480848, showed an enhanced in vitro and in vivo profile versus SB-435495 and has been selected for progression to man. Topics: 1-Alkyl-2-acetylglycerophosphocholine Esterase; Animals; Cytochrome P-450 CYP2D6 Inhibitors; Enzyme Inhibitors; Humans; In Vitro Techniques; Kinetics; Phospholipases A; Phospholipases A2; Pyrimidinones; Rabbits; Recombinant Proteins	2003

Article

Year

The identification of clinical candidate SB-480848: a potent inhibitor of lipoprotein-associated phospholipase A2.

Bioorganic & medicinal chemistry letters, 2003, Mar-24, Volume: 13, Issue:6

Modification of the pyrimidone 5-substituent in clinical candidate SB-435495 has given a series of inhibitors of recombinant lipoprotein-associated phospholipase A(2) with sub-nanomolar potency. Cyclopentyl fused derivative 21, SB-480848, showed an enhanced in vitro and in vivo profile versus SB-435495 and has been selected for progression to man.

Topics: 1-Alkyl-2-acetylglycerophosphocholine Esterase; Animals; Cytochrome P-450 CYP2D6 Inhibitors; Enzyme Inhibitors; Humans; In Vitro Techniques; Kinetics; Phospholipases A; Phospholipases A2; Pyrimidinones; Rabbits; Recombinant Proteins

2003